1 October 2012 in American Journal of Ophthalmology
1 June 2003 in Nephron Clinical Practice
Background/Aims: We investigated whether urinary podocytes are present in septic patients with methicillin-resistant Staphylococcus aureus (MRSA)-associated glomerulonephritis and whether polymyxin B-immobilized fiber (PMX-F) treatment affects proteinuria and urinary podocyte excretion in these patients. Methods: Twenty septic patients with MRSA-associated glomerulonephritis (mean age: 63.7 years) and 80 septic patients whose MRSA infection was not followed by glomerulonephritis (mean age: 60.5 years) were included in this study. All septic patients were treated with fosfomycin sodium, β-lactams, arbekacin sulfate, and teicoplanin, or a combination of these. Twenty septic patients with MRSA-associated glomerulonephritis were randomly assigned to one of two treatments: PMX-F treatment (group A, n = 10) and conventional treatment (group B, n = 10). PMX-F treatment was repeated twice. Results: Urinary podocytes and urinary protein excretion were not detected in MRSA septic patients without glomerulonephritis. However, urinary podocytes (1.7 ± 0.6 cells/ml) and proteinuria (2.6 ± 0.6 g/d) were detected in the 20 septic patients with MRSA-associated glomerulonephritis. Plasma endotoxin levels were decreased from 13.6 ± 4.6 pg/ml to 6.6 ± 2.2 pg/ml (p < 0.05) in group A. Levels in group B, however, showed little difference after treatment. Urinary podocytes were reduced in group A (from 1.8 ± 0.6 cells/ml to 0.4 ± 0.2 cells/ml, p < 0.01) as was urinary protein excretion (from 3.0 ± 0.5 g/d to 0.8 ± 0.4 g/d, p < 0.01) but urinary podocytes and protein excretion levels showed little difference after treatment in group B. Conclusion: PMX-F treatment may be effective in reducing urinary protein and urinary podocyte excretion in septic patients with MRSA-associated glomerulonephritis.
11 October 2020 in Therapeutic Apheresis and Dialysis
The novel coronavirus disease outbreak started in Wuhan, China, in December 2019 and has since spread rapidly worldwide. As almost all patients with end‐stage kidney disease have been treated with HD in Japan, they have a higher risk of infection than the healthy population. Moreover, the complications of renal failure, such as hypertension and cardiovascular diseases, appear to be a risk factor of death owing to novel coronavirus disease. The reported morbidity and mortality rates of novel coronavirus disease are significantly higher in dialysis patients than in the healthy population. No treatment for novel coronavirus disease has yet been developed; thus, countermeasures to prevent the spread of coronavirus disease in dialysis facilities must be rapidly established. The latest findings on novel coronavirus disease in patients with end‐stage kidney disease and the guidelines for countermeasures against the spread of novel coronavirus disease worldwide are summarized in this review.
1 January 2018 in Case Reports in Orthopedics
The treatment strategy and surgical indication for coronoid process fractures are not clear. Many methods of surgery have been described. We report on the use of arthroscopic osteosynthesis for this type of fracture. This method is minimally invasive and effective for confirming the reduction, and it is advantageous for postoperative pain and early recovery after surgery.
22 September 2000 in Nephron
1 August 2025 in Arthroplasty
Background: Although reverse shoulder arthroplasty (RSA) is a popular treatment, its efficacy in patients with failed rotator cuff repair (ARCR) remains unclear. In this study, we aimed to evaluate the clinical results of RSA for following failed ARCR. We hypothesized that RSA after failed ARCR would lead to improved clinical outcomes comparable to those of RSA performed without prior surgeries. Methods: Between January 2017 and December 2022, 143 patients underwent RSA at our institution. We included 85 patients who met the study criteria and followed them for a minimum of 2 years. The patients were divided into two groups: those who underwent RSA for failed ARCR (group A: 25 patients; mean age, 77.7 years) and those who underwent primary RSA (group B: 60 patients; mean age, 77.9 years). The University of California, Los Angeles (UCLA) scores, Japanese Orthopaedic Association (JOA) scores, range of motion (ROM), Numerical Rating Scale (NRS) scores, and complication rates were compared between the two groups. Results: At the 2-year postoperative follow-up, both groups showed significant improvements in all items. Postoperative outcome or complication rate demonstrated no significant difference between group A and group B: UCLA scores (29.7 ± 3.9 vs 29.3 ± 3.6), JOA scores (87.4 ± 6.1 vs 87.4 ± 8.6), ROM forward elevation (129.1 ± 20.1 vs 133.9 ± 24.1), ROM external rotation (29.1 ± 12.7 vs 29.4 ± 10.7), ROM internal rotation (2.4 ± 1.0 points vs 2.3 ± 1.1 point), NRS scores (0.9 ± 1.2 vs 1.1 ± 1.3), and complication rates (4.0% vs 3.3%). Group A exhibited improvement in all items, and the results were comparable to those in group B. Conclusions: RSA in patients with prior rotator cuff repair demonstrated similar functional outcomes and complication rates to those in patients who underwent RSA without prior surgeries. The study demonstrated that prior ARCR would not be a negative predictor. For patients who are afraid of or cannot consent to artificial joint surgery, recommending ARCR first may be an option. Graphical